It depends on the standard you follow. As of September 2026, Caris Life Sciences, Inc. (CAI) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones Islamic, and fails MSCI and FTSE.
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 4.91% / 30% · (Cash+Inv) / Mkt Cap (36m) 9.58% / 30% · Interest income / Revenue 2.30% / 5% | Pass |
| S&P Global | Debt / Mkt Cap (36m) 4.91% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 9.58% / 33% · Receivables / Mkt Cap (36m) 1.66% / 49% · Interest income / Revenue 2.30% / 5% | Pass |
| Dow Jones Islamic | Debt / Mkt Cap (24m) 4.91% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 9.58% / 33.33% · Receivables / Mkt Cap (24m) 1.66% / 33.33% · Interest income / Revenue 2.30% / 5% | Pass |
| MSCI | Debt / Avg Assets (4Q) 32.5% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 66.7% / 33.33% · Receivables / Avg Assets (4Q) 9.49% / 33.33% · Interest income / Revenue 2.30% / 5% | Fail |
| FTSE | Debt / Total Assets 31.3% / 33.33% · (Cash+ST Inv) / Total Assets 61.1% / 33.33% · (Cash+Recv) / Total Assets 71.7% / 33.33% · Interest income / Revenue 2.30% / 5% | Fail |
It depends on the standard you follow. As of September 2026, Caris Life Sciences, Inc. (CAI) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones Islamic, and fails MSCI and FTSE.
Yes. Caris Life Sciences, Inc. is within every AAOIFI limit: debt and interest-bearing cash and investments under 30% of its 36-month average market cap, and interest income under 5% of revenue.
About 2.30% of each dividend: Caris Life Sciences, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.
Caris Life Sciences, Inc. (NASDAQ: CAI) is a Healthcare company (Biotechnology) with a market capitalization of $6.0B. The Maz Rating grades it against the other companies in its sector.
Caris Life Sciences, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $21.00, Caris Life Sciences, Inc. trades at 62.5x trailing earnings, 5.7x sales and 9.3x book value, with an EV/EBITDA of 37.3. Over the last twelve months it generated about $1.0B of revenue and $96M of net income. It runs a gross margin of 69.1%, an operating margin of 13.4% and a net margin of 9.2%. It shows return on equity of 16.0%, return on invested capital of 12.5% and a free cash flow yield of 0.9%. On the balance sheet: a debt-to-equity ratio of 0.72 and a current ratio of 6.71. Over the past 52 weeks the share price ranged from $14.19 to $36.50, with a beta of 0.70.
Caris Life Sciences, Inc. does not currently pay a dividend.
9 Wall Street analyst ratings cover the stock: 7 Buy and 2 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Caris Life Sciences, Inc. operates as a leading "TechBio" firm, harnessing artificial intelligence to deliver comprehensive molecular profiling services to clients both in the United States and internationally. The company is dedicated to transforming medical care by innovating and bringing to market advanced solutions that leverage molecular data and sophisticated machine learning algorithms. Its extensive suite of molecular diagnostic offerings includes MI Profile, a specialized solution analyzing tissue samples, and Caris Assure, a blood-based test designed for cancer treatment applications. Furthermore, Caris provides research and development support to biopharmaceutical customers, encompassing laboratory delivery, strategic data insights, and dedicated research initiatives. Established in 2008, the company maintains its corporate headquarters in Irving, Texas.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.